AstraZeneca PLC
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca Core net finance expense: -$340M in Q2 2026, up 12.2% from a year earlier. That is the lowest of the 23 quarters on record here.
Latest, Q2 2026
-340
Period ended Jun 30, 2026
Change on a year earlier
+12.2%
-303 in Q2 2025
History
23 quarters
Since Q4 2020
Sources
23
Documents cited below
Where the Q2 2026 figure comes from
“|| Net finance expense | | (355) | | | – | | | – | | 15 | | (340) | 13 | 8”
Source: Form 6-K FY2026Q2 Earnings Release ↗
Reported in Form 6-K / 20-F Reported-to-Core Reconciliation.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). AstraZeneca Core net finance expense ($M), quarterly Q4 2020–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/core-net-finance
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.